Feature

Computed Tomography (CT) procedure rates have declined by an average annual 5.5 percent in the United States over the past two years, diverging from a previous decade-long growth trend, according to a survey conducted by IMV Medical Information Division.

Home January 21, 2014
Home
TCT GE XD Clear 3-D with clear depth illumination Oct 2013 356
Feature | Dave Fornell

The Cardiovascular Research Foundation’s Transcatheter Cardiovascular Therapeutics (TCT) 2013 offers many new insights about the latest cardiovascular technologies and treatment techniques. These are my choices for the most innovative new or futuristic technologies highlighted on the show floor or in sessions at TCT 2013.

Home January 20, 2014
Home
Technology

Toshiba America Medical Systems’ Dose Tracking System allows clinicians to track x-ray skin dose exposure in real time during interventional procedures.

Home January 20, 2014
Home
News

A new internal defibrillator that treats patients with major heart risks, is being used at Henry Ford Hospital, Detroit.

Home January 17, 2014
Home
News

Through the existing Innovator in Residence (IIR) program, HIMSS and the U.S. Department of Health and Human Services (HHS) are collaborating to move forward on the creation of a nationwide patient data matching strategy.

Home January 17, 2014
Home
Technology | Dave Fornell

The U.S. Food and Drug Administration (FDA) granted U.S. market approval for Medtronic’s self-expanding transcatheter aortic valve replacement (TAVR) CoreValve System. It is the first self-expanding TAVR valve to be approved in the United States and the second TAVR valve to achieve FDA approval.

Home January 17, 2014
Home
sorin perceval s heart valve repair cardiovascular surgery
Feature

Cardiothoracic and Vascular Surgeons (CTVS) is the first practice in Texas to implant a Sorin Perceval S self-anchoring aortic heart valve as part of a new clinical trial.

Home January 17, 2014
Home
News

Providers report that despite vendor efforts, clinical decision support (CDS) reference products are still not integrated enough to deliver the strategic direction providers are looking for.

Home January 16, 2014
Home
Medtronic, corevalve, edwards, litigation, TAVR, TAVI
Feature | Dave Fornell

In a move that calls into question the future of transcatheter valve competition in the United States, a jury in the Federal District Court of Delaware decided Jan. 15 the Medtronic CoreValve infringes on transcatheter device patents held by Edwards Lifesciences Corp. Medtronic said it intends to appeal the decision.

Home January 15, 2014
Home
News

A new “fluid biopsy” technique that could identify patients at high risk of a heart attack by identifying specific cells as markers in the bloodstream has been developed by a group of researchers at The Scripps Research Institute (TSRI).

Home January 15, 2014
Home
mri systems clinical trial study university pennsylvania creatine CEST map
Feature

A new magnetic resonance imaging (MRI) method to map creatine at higher resolutions in the heart may help clinicians and scientists find abnormalities and disorders earlier than traditional diagnostic methods.

Home January 15, 2014
Home
cath lab stents bioresorbable amaranth fortitude scaffold
Feature

Amaranth Medical announced the closing of an equity investment by Boston Scientific Corp.

Home January 14, 2014
Home
heart valve repair clinical trial study edwards lifesciences sapien 3
Feature

Edwards Lifesciences Corp. announced that it received investigational device exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to initiate a clinical trial of the Sapien 3 transcatheter aortic heart valve in the treatment of intermediate risk patients with severe symptomatic aortic stenosis.

Home January 14, 2014
Home
Technology

MediValve Ltd. announced that it has received clearance of a Pre-Marketing Notification Application (510(k)) from the U.S. Food and Drug Administration (FDA) for its acWire Guidewire.

Home January 14, 2014
Home
News

A clinical trial found that Xa inhibitor edoxaban met the primary efficacy endpoint of non-inferiority compared to warfarin for the prevention of stroke or systemic embolic events (SEE) in patients with non-valvular atrial fibrillation (NVAF).

Home January 14, 2014
Home
Subscribe Now